BioSpace News Archive

LAVA Therapeutics N.V. today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Oncolytics Biotech ® Inc. announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

Accuray Incorporated announced an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department’s capabilities.

Crescita Therapeutics Inc. today announced that it has agreed to acquire all of the non-real estate business assets of Occy Laboratory Inc., (“Occy”), a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the “Transaction”).

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflow.

Cocrystal Pharma, Inc.’s novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies.

Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.